Argentine Pharma Revenue Skyrockets in H1

Argentina’s pharmaceutical industry reported a striking 88.6% surge in revenue for the first half of the year, according to an official statement.

Specifically, sales from domestically produced drugs climbed by 93%. Resales of imported medicines also rose, marking an 80.4% uptick.

In addition, exports of Argentine pharmaceuticals swelled by 82.4%.

Interestingly, this outpaced the country’s general consumer price index, which only advanced by 50.7%.

Revenue from locally produced medicines reached ARS 457.45 billion, approximately $1.25 billion.

Meanwhile, imported medicines brought in ARS 203.24 billion, or roughly $556 million. Export revenue stood at ARS 40.8 billion, nearly $112 million.

Argentina sources its pharmaceutical imports from India, China, Germany, the U.S., and Switzerland, among others.

Background

The pharma sector has long been a cornerstone in Argentina’s economy, constantly evolving in innovation and distribution.

Lately, governmental focus has shifted toward boosting local drug production, which seems to be effective, as evident from the latest figures.

However, high revenue doesn’t necessarily translate to affordability for the general public. Rising sales could indicate escalating medicine costs, posing a public health challenge.

It’s crucial to strike a balance between sector growth and public access to vital medications.

Examining the long-term effects of this revenue spike on consumer affordability may provide key insights for upcoming policy decisions.

This article was drafted with automated assistance and reviewed before publication. How we use AI · Report an error